InnFocus, the US-based developer of a glaucoma drainage system, has closed a $33.9m series C round featuring optical product manufacturer Hoya Corporation and pharmaceutical firm Santen Pharmaceutical.
In addition to the Japan-based corporates, investors in the round also included Saints Capital Everest and Crown Venture Fund.
InnFocus is working on a drainage system called MicroShunt to treat patients suffering from the eye condition glaucoma. The device is expected to enter the final phase of clinical testing next month, and the funding will help InnFocus complete those trials.
The company had raised $32.8m for the round as of the end of September. It had previously raised $15.5m in funding across two rounds in 2011 and 2013, according to regulatory filings.